Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology
that has revolutionized the way we conceive immunotherapy. The impressive clinical results …

Gene therapy is becoming an influential part of the rapidly increasing armamentarium of
biopharmaceuticals for improving health and combating diseases. Currently, three gene …

Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled
by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and …

Type I interferons (IFN-I) play a critical role in human antiviral immunity, as demonstrated by
the exceptionally rare deleterious variants of IFNAR1 or IFNAR2. We investigated five …

Immunotherapy with T cell modified with gamma-retroviral or lentiviral (LV) vectors to
express a chimeric antigen receptor (CAR) has shown remarkable efficacy in clinical trials …

MicroRNAs (miRNAs) are small regulatory RNAs that act in an entangled web of interactions
with target mRNAs to shape the cellular protein landscape by post‐transcriptional control of …

The widespread clinical implementation of gene therapy requires the ability to stably
integrate genetic information through gene transfer vectors in a safe, effective, and …

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in
haematological malignancies. However, although viral vector-based methods are effective …

Gene therapy protocols require robust and long-term gene expression. For two decades,
retrovirus family vectors have offered several attractive properties as stable gene-delivery …

Molecular medicine has entered a high-tech age that provides curative treatments of
complex genetic diseases through genetically engineered cellular medicinal products. Their …